HAVCR1 and chronic kidney disease: Consistent with our finding that simvastatin but not pravastatin reduces KIM-1, lipophilic statins (atorvastatin) were reported to be more protective than hydrophilic statins (rosuvastatin) in chronic kidney disease [64,65].